131 related articles for article (PubMed ID: 2591571)
21. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
22. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Ferone D; Selleri A; Landi ML; Schettini G; Nappi C
Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
[TBL] [Abstract][Full Text] [Related]
23. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
Weingrill CO; Mussio W; Moraes CR; Portes E; Castro RC; Lengyel AM
Fertil Steril; 1992 Feb; 57(2):331-5. PubMed ID: 1735484
[TBL] [Abstract][Full Text] [Related]
24. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
Gianola D; Pedroncelli A; Montini M; Tengattini F; Pagani MD; Cortesi L; Cappi MP; Gherardi F; Lancranjan I; Pagani G
Gynecol Endocrinol; 1991 Sep; 5(3):213-6. PubMed ID: 1776507
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Lancranjan I; Lombardi G; Schettini G
J Endocrinol Invest; 1992 Mar; 15(3):173-6. PubMed ID: 1624676
[TBL] [Abstract][Full Text] [Related]
26. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
27. [Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
Tokhunts KA
Georgian Med News; 2007 Jan; (142):14-9. PubMed ID: 17327626
[TBL] [Abstract][Full Text] [Related]
28. Mixed pituitary tumours--effects of bromocriptine treatment: Parlodel MR and Parlodel LAR.
Zgliczyński W; Zgliczyński S; Makowska A; Słowinska-Srzednicka J; Janik J; Jeske W; Walecki J
Endokrynol Pol; 1992; 43(3):242-9. PubMed ID: 1345565
[TBL] [Abstract][Full Text] [Related]
29. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
30. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.
Moro M; Maraschini C; Toja P; Masala A; Alagna S; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
Horm Res; 1991; 35(3-4):137-41. PubMed ID: 1806467
[TBL] [Abstract][Full Text] [Related]
31. Long-acting injectable bromocriptine treatment for macroprolactinomas.
Van Cutsem EJ; Lamberts SW
Neth J Med; 1988 Apr; 32(3-4):112-7. PubMed ID: 3362265
[No Abstract] [Full Text] [Related]
32. Effect of injectable bromocriptine in patients with Cushing's disease.
Invitti C; De Martin M; Danesi L; Cavagnini F
Exp Clin Endocrinol Diabetes; 1995; 103(4):266-71. PubMed ID: 7584534
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine.
Tartagni M; Nicastri PL; Diaferia A; Di Gesù I; Loizzi P
Clin Exp Obstet Gynecol; 1995; 22(4):301-6. PubMed ID: 8777784
[TBL] [Abstract][Full Text] [Related]
34. Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomas.
Archer DF; Lattanzi DR; Moore EE; Harger JH; Herbert DL
Am J Obstet Gynecol; 1982 Jul; 143(6):620-5. PubMed ID: 7201244
[TBL] [Abstract][Full Text] [Related]
35. Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections.
Paoletti AM; Cagnacci A; Mais V; Ajossa S; Guerriero S; Murgia C; Depau GF; Serra GG; Melis GB
Clin Exp Obstet Gynecol; 1994; 21(2):124-8. PubMed ID: 8070116
[TBL] [Abstract][Full Text] [Related]
36. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
37. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
38. Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.
Abs R; Parizel PM; Beckers A
J Endocrinol Invest; 1991 Feb; 14(2):135-8. PubMed ID: 1905737
[TBL] [Abstract][Full Text] [Related]
39. [Short-term effect of delayed-action injectable bromocriptine in macroprolactinoma. French multicenter study].
Brue T; James-Deidier A; Louvet JP; Dewailly D; Roger P; Schlienger JL; Schaison G; Hartemann P; Jaquet P
Ann Endocrinol (Paris); 1991; 52(4):273-82. PubMed ID: 1818531
[TBL] [Abstract][Full Text] [Related]
40. Lack of tumor reduction in hyperprolactinemic women with extrasellar macroadenomas treated with bromocriptine.
Boulanger CM; Mashchak CA; Chang RJ
Fertil Steril; 1985 Oct; 44(4):532-5. PubMed ID: 4054327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
